Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis - Summary - MDSpire

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • By

  • Jeffrey Crowley

  • Eingun James Song

  • Linda Stein-Gold

  • Paolo Gisondi

  • Christopher G. Bunick

  • Vishvas Garg

  • Emanuele Leoncini

  • Blair Kaplan

  • Richard Ta

  • Bang Truong

  • Dolly Sharma

  • Bruce Strober

  • July 2, 2026

  • 0 min

Share

Objective:

To compare the clinical efficacy of Risankizumab (RZB) with Icotrokinra (ICO) in adult patients with moderate-to-severe psoriasis using a matching-adjusted indirect comparison (MAIC).

Approach:
  • Study Design: This MAIC compares clinical efficacy between RZB and ICO in adult patients with moderate-to-severe psoriasis, utilizing individual patient data from phase 3 trials.
  • Data Sources: Included studies were phase 3, multinational randomized controlled trials that enrolled adults with moderate-to-severe plaque psoriasis, with endpoints assessed primarily at week 16 and beyond.
Key Findings:
  • AsignificantlyhigherproportionofpatientstreatedwithRZBachieved≥75%improvementinPASI(PASI75)comparedtoICO,withsimilartrendsobservedforPASI90,PASI100,Investigator’sGlobalAssessmentof0or1(IGA0/1),andIGA0.ResultsindicatethatRZBmayprovidegreaterclinicalefficacythanICOovera52-weekperiodbasedonindirectcomparisons.
Interpretation:

The findings suggest that RZB may be more effective than ICO in treating moderate-to-severe psoriasis, based on indirect comparisons.

Limitations:
  • Theanalysisisbasedonindirectcomparisons,whichmaybesensitivetodifferencesinpopulationcharacteristics.OnlystudiespublishedbeforeMarch31,2026,wereincluded,whichmaylimitthecomprehensivenessofthedata.
Conclusion:

The study provides insights into the comparative efficacy of RZB and ICO for moderate-to-severe psoriasis.

Original Source(s)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

  • July 2, 2026

Related Content

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions